Prostate cancer (PCa) is the third most common malignancy and the fifth cause of cancer death in men worldwide [1], with the number of diagnoses markedly increased after the introduction of the prostate-specific antigen (PSA) screening. This evidence concerns the gene KLK3 and Familial prostate cancer.